Under TAC treatment, GCN5 overexpression led to worse cardiac function than the control group (Fig. 2A–D), as well as by the increase in heart weight (HW)/body weight (BW), HW/tibia length (TL), and lung weight (LW)/BW (Fig. 2E–G). This evidence concerns the gene KAT2A and persistent truncus arteriosus.